Malignancy-associated catabolite
US5202482A · kind A · utility
Assignee
Inventor
Key dates
| Filing date | Oct 13, 1989 |
| Grant date | Apr 13, 1993 |
| Priority date | — |
| Expiry date | Oct 13, 2009 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N33/57488
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
The present invention arises from the discovery of an endogenous malignancy-associated catabolite characterized by (i) a molecular weight of about 135 daltons as determined by mass spectrum analysis; (ii) a UV absorption maximum at 237 nm; (iii) a 15 centimeter C18 HPLC column retention time of from about 1.00 to about 2.00 minutes as compared to a retention time at a 1 ml/minute flow rate of about 2.5 to about 3.0 minutes for an internal standard marker; (iv) containing no aromatic ring structures, containing one methyl group at the 1-position and one methyl group at the 6-position of an alpha carbon chain, and containing at least one nitrogen moiety as determined by nuclear magnetic resonance; and (v) being present in elevated amounts in the urine substantially exclusively of individuals suffering from malignant conditions. Further, the invention provides a method of monitoring the effectiveness of treatment of an individual treated for a malignant condition and a method for determining the presence or absence of a malignant condition in an individual, which methods comprise analyzing a urine sample of the individual for the concentration of malignancy-associated catabolite there…
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.